About 70 percent of Americans with history of heart disease, stroke take aspirin
the ONA take:
About 70% of Americans who have heart disease or a stroke regularly take low-dose aspirin, according to a report from the U.S. Centers for Disease Control and Prevention (CDC).
For the study, researchers from the U.S. CDC analyzed data from the 2013 Behavioral Risk Factor Surveillance System, which included patients surveyed via telephone from 20 states and the District of Columbia. They found that 70.8% of respondents take low-dose aspirin regularly. More importantly, nearly 94% of those with a history of heart problems reported taking low-dose aspirin regularly to prevent a heart attack
In addition, approximately 80% reported taking it for stroke prevention and 76% said they take it to prevent both. Only 4% of respondents reporting taking low-dose aspirin for pain relief only.
Mississippi had the highest aspirin use with 72% of patients with heart problems regularly taking low-dose aspirin. Missouri had the lowest with 44%. Researchers found the males, people 65 years and older, whites, and patients with at least two cardiac risk factors are more likely to take aspirin compared with other groups.
The findings suggest that clinicians should target patients reporting lower regular aspirin use like Hispanics, blacks, and those who did not attain a high school diploma.
About 70% of Americans who have heart disease or a stroke regularly take low-dose aspirin.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|